Danoprevir - Array BioPharma/Roche/Ascletis
Alternative Names: ASC-08; Ganovo; ITMN-191; ITMN-B; R-7227; RG-7227; RO-5190591Latest Information Update: 05 Nov 2023
At a glance
- Originator Array BioPharma; InterMune
- Developer Ascletis; Roche
- Class Antivirals; Carboxylic acids; Cyclopropanes; Isoindoles; Macrocyclic compounds; Pyrrolidines; Small molecules; Sulfonamides
- Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Hepatitis C
- No development reported COVID 2019 infections
Most Recent Events
- 28 Dec 2022 No development reported - Clinical-Phase-Unknown for COVID-2019 infections (Combination therapy, Treatment-experienced) in China (PO)
- 28 Dec 2022 No development reported - Clinical-Phase-Unknown for COVID-2019 infections (Combination therapy, Treatment-naive) in China (PO)
- 25 Aug 2020 Danoprevir is launched for Hepatitis C (combination therapy, treatment Naïve) in China (PO)